Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial

Simple item page
dc.contributor.authorGoss, G. D.
dc.contributor.authorCobo, M.
dc.contributor.authorLu, S.
dc.contributor.authorSyrigos, K.
dc.contributor.authorLee, K. H.
dc.contributor.authorGoker, E.
dc.contributor.authorGeorgoulias, V.
dc.contributor.authorLi, W.
dc.contributor.authorIsla, D.
dc.contributor.authorMorabito, A.
dc.contributor.authorMin, Y. J.
dc.contributor.authorArdizzoni, A.
dc.contributor.authorJian, H.
dc.contributor.authorYu, Y.
dc.contributor.authorBender, S.
dc.contributor.authorCseh, A.
dc.contributor.authorFelip, E.
dc.contributor.authoraffiliation[Goss, G. D.] Univ Ottawa, Ottawa, ON, Canada
dc.contributor.authoraffiliation[Cobo, M.] Hosp Carlos Haya, Malaga, Spain
dc.contributor.authoraffiliation[Lu, S.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai, Peoples R China
dc.contributor.authoraffiliation[Jian, H.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai, Peoples R China
dc.contributor.authoraffiliation[Yu, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai, Peoples R China
dc.contributor.authoraffiliation[Syrigos, K.] Athens Sch Med, Athens, Greece
dc.contributor.authoraffiliation[Lee, K. H.] Chungbuk Natl Univ, Coll Med, Cheongju, South Korea
dc.contributor.authoraffiliation[Goker, E.] Ege Univ, Fac Med, Izmir, Turkey
dc.contributor.authoraffiliation[Georgoulias, V.] Univ Hosp Heraklion, Iraklion, Greece
dc.contributor.authoraffiliation[Li, W.] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China
dc.contributor.authoraffiliation[Isla, D.] Hosp Lozano Blesa, Zaragoza, Spain
dc.contributor.authoraffiliation[Morabito, A.] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
dc.contributor.authoraffiliation[Min, Y. J.] Ulsan Univ Hosp, Ulsan, South Korea
dc.contributor.authoraffiliation[Ardizzoni, A.] Policlin S Orsola, Bologna, Italy
dc.contributor.authoraffiliation[Bender, S.] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
dc.contributor.authoraffiliation[Cseh, A.] Boehringer Ingelheim RCV GmbG & Co KG, Vienna, Austria
dc.contributor.authoraffiliation[Felip, E.] Vall dHebron Univ Hosp, Barcelona, Spain
dc.date.accessioned2025-01-07T12:15:00Z
dc.date.available2025-01-07T12:15:00Z
dc.date.issued2019-11-01
dc.identifier.doi10.1016/j.jtho.2019.09.165
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086419334938/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24371
dc.identifier.wosID494945000074
dc.issue.number11
dc.issue.number2
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.numberS1185-S1185
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectlung SCC
dc.subjectafatinib
dc.subjecterlotinib
dc.subjectsecond-line
dc.titleSecond-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number14
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía